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A B S T R A C T
Background: Hepatitis E virus (HEV) infection is increasingly recognized as a cause of hepatitis in developed
countries. A high HEV IgG seroprevalence in humans and pigs is reported as well as sporadic clinical cases of
autochtonous HEV but there are currently no data available on the clinical burden of HEV in Belgium.
Objectives: The objective of the current study was to evaluate the actual clinical burden of HEV infections in our
tertiary care center in Flanders, Belgium.
Study design: In the setting of Ghent University Hospital, patients were assessed for the presence of HEV IgG and
IgM as well as HEV RNA if no other cause was found for one of the following clinical presentations: a) elevation
of liver enzymes in post-liver transplant; b) suspicion of acute or toxic hepatitis; c) unexplainable elevation of
liver enzymes; d) cirrhosis with acute-on-chronic exacerbation.
Results: In a period of 39 months (January 2011–April 2014) 71 patients were enrolled. HEV IgG was found
positive in 13 (18,3%) patients; HEV IgM in 6 patients (8,5%) and HEV RNA in 4 (5,6%) patients. All HEV IgM/
RNA positive patients were male, aged 41–63, and classiﬁed in the clinical groups a), b) or d). HEV IgG ser-
oprevalence was slightly higher but not signiﬁcantly diﬀerent from the seroprevalence in the general population
in this region in Belgium previously reported to be 14% (p-value 0.41) by our group.
Conclusions: HEV should be considered as a cause of liver pathology especially in middle-aged men with ele-
vation of liver enzymes.
1. Background
Hepatitis E virus (HEV) is a small, non-enveloped, single stranded
RNA virus. Four HEV genotypes exist. HEV genotypes 1 and 2 are ty-
pically associated with human epidemic outbreaks in developing
countries. They are transmitted between humans by the fecal-oral
route. By contrast, HEV genotypes 3 and 4 are transmitted foodborne
and zoonotically from animal reservoirs. They usually occur as sporadic
cases and are emerging pathogens in the developed world [1–6]. HEV
can be complicated by serious complications such as neurologic dis-
orders. Moreover, unlike the other HEV genotypes, HEV genotype 3 can
be associated with chronic infection (deﬁned as the presence of HEV
RNA in serum or stool ≥6 months) [1–3,6–8]. Immunocompromised
persons are at risk [4,8].
Hepatitis E virus (HEV) infection is increasingly recognized as a
cause of hepatitis in developed countries [6,9]. A high HEV IgG ser-
oprevalence in humans and pigs is reported in Belgium [10,11]. Van
Hoecke et al. observed a seroprevalence rate of 14% in humans in East
and West Flanders [10]. Also, sporadic cases of autochthonous HEV
infection were described [12,13].
Clinical features of a HEV infection are diverse. Most of the infec-
tions with HEV are asymptomatic. If symptoms occur, the clinical pic-
ture varies from mild disease to (sub)acute or fulminant liver failure.
Especially patients with pre-existing liver disease are at risk for serious
clinical manifestations and death [7]. Routine laboratory parameters
are often nonspeciﬁc. Therefore a HEV infection may be
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indistinguishable from other clinical conditions such as other causes of
viral hepatitis, autoimmune hepatitis or drug-induced liver injury
[1–9,14].
2. Objectives
The objective of the current study was to evaluate the clinical
burden of HEV infections in the Ghent University Hospital, Belgium,
using both serological assays (anti-HEV IgM and IgG) and PCR (HEV
RNA).
3. Study design
In the setting of Ghent University Hospital, clinically suspected
patients for HEV infection were assessed for the presence of anti-HEV
IgM and IgG as well as HEV RNA. The study was approved by the
Ethical Committee of Ghent University Hospital under Belgian
Registration number B670201110350. After exclusion of other plau-
sible causes during routine diagnostic workout, patients with the fol-
lowing clinical presentations were included: a) an elevation of liver
enzymes post-liver transplant; b) suspicion of acute or toxic hepatitis; c)
unexplainable elevation of liver enzymes; d) cirrhosis with acute-on-
chronic exacerbation.
3.1. Samples
In total, 71 patients were included in this study during a period of
39 months (January 2011–April 2014). From each included patient,
two serum tubes were collected: one for HEV serology and one for HEV
PCR. Serum for serology and PCR was stored separately at −20 °C and
−80 °C respectively prior to analysis.
3.2. Serology
HEV serology was performed using Wantai anti-HEV IgM and IgG
commercial ELISA assays (Wantai Biological Pharmacy, Beijing, China).
The assays were executed in accordance with the manufacturer’s in-
structions. Signal to cut-oﬀ ratios (s/co) were interpreted as prescribed.
3.3. PCR
HEV RNA was determined on all clinical samples using a commer-
cial HEV RT-PCR assay targeting ORF 3 (RealStar® HEV RT-PCR Kit 1.0,
Altona Diagnostics GmbH, Hamburg, Germany). The NucliSENS®
easyMAG® (bioMerieux, Marcy l’Etoile, France) automated nucleic acid
extraction system was used for RNA extraction (bioMérieux, Boxtel, The
Netherlands). The Altona assay was performed according to the man-
ufacturer’s instructions. PCR assays were performed on the CFX96 real-
time PCR detection system (Bio-Rad, Nazareth, Belgium).
3.4. Sequencing and phylogenetic analysis
Sequencing and phylogenetic analysis was performed in the
National Reference Centre for Viral Hepatitis (NRC) (WIV-ISP, Brussels,
Belgium).
The sequencing was done by an in-house developed method on the
ABI3130 automatic capillary sequencer. The primers used are ampli-
fying a fragment of 348 bp in the ORF2 region of the HEV genome [16].
The reference set consisted of 18 diﬀerent know strains of human HEV
and the prototype US strain of swine HEV [17].
Sequence analyses, alignments and phylogenetic trees were realized
by the statistical programs DNASTAR Lasergene 10 Core Suite
(DNASTAR®, Madison, USA) and the MEGA 5.2 software [18].
3.5. Statistics
Statistical analysis was carried out using Student t-test in SPSS
(IBM® SPSS® Statistics, version 22).
4. Results
In a period of 39 months (January 2011 until April 2014), 71 pa-
tients were enrolled. The studied population consisted of 41 men (58%)
and 30 women (42%). The average age was 48years (range 15–75
years). The majority of patients (26 patients, 37%) presented with a
clinical suspicion of acute or toxic hepatitis (group b). Besides, there
were 21 patients (30%) with an elevation of liver enzymes (group c), 17
post-liver transplant patients (24%) with an elevation of liver enzymes
(group a), 4 patients (5,6%) with cirrhosis with acute-on-chronic ex-
acerbation (group d) and 3 patients who belonged to two categories
(Table 1).
HEV IgG was found positive in 13 patients (18,3%), HEV IgM in 6
patients (8,5%). HEV RNA was detected in 4 out of 6 IgM positive
patients: 3 patients were found HEV RNA positive on the study sample
using both our commercial PCR method as well as the commercial PCR
used in the NRC; the last patient initially tested negative for HEV RNA
in both centers (study sample, 29/08/2013), but HEV RNA was de-
tected in the NRC on an earlier sample of the same patient (09/07/
2013, with elevation of liver enzymes at that time).
Sequencing revealed two strains belonged to genotype 3, one was
subtyped as genotype 3f, the other as genotype 3 h. Sequencing of the
other two strains failed technically presumably due to a low viral load
in the samples. Table 2 provides a summary of these results.
All four HEV IgM and RNA positive patients were male, aged 41–63
years. The patients presented with a varying clinical picture: two of
these patients had an acute or toxic hepatitis (group b), one was a
cirrhosis patient with an acute-on-chronic exacerbation (group d) and
the last was a liver transplant patient with elevation of liver enzymes
(group a). Liver function parameters (ALT, AST, gamma-GT and alka-
line phosphatase) and bilirubin at the moment of presentation are
displayed in Table 2. All patients showed disturbed liver enzymes. Bi-
lirubin was increased in 2/4 patients. The clinical picture ranged from
Table 1
Overview of the included patients and study results.
Group Clinical picture Age Mean (Min-
Max)
Gender (M/F) Number of patients HEV IgG positive HEV IgM positive HEV RNA positive
a Elevation of liver enzymes post-liver
transplantation
54 (27–75) 11/6 17 2 2 1
b Acute or toxic hepatitis 46 (17–75) 16/10 26 6 2 2
c Elevation of liver enzymes 45 (15–63) 9/12 21 3 1 0
d Cirrhosis with acute-on-chronic exacerbation 56 (31–69) 3/1 4 2 1 1
e Patients belonging to two categories 46 (31–57) 2/1 3 0 0 0
Total 48 (15–75) 41/30 71 13 (18,3%) 6 (8,5%) 4 (5,6%)
Overview of the included patients and study results.
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subclinical (patient 4) over mild/moderate disease with spontaneous
recuperation (patient 1 and 3) to an acute and severe hepatitis which
necessitated an urgent liver transplantation (patient 2). None of the
patients developed a chronic infection.
HEV IgG seroprevalence in this study, 18,3%, was slightly higher
but not signiﬁcantly diﬀerent from the seroprevalence in the general
population in Belgium reported to be 14% (p-value 0.41) [10].
5. Discussion
HEV genotype 3 is described as the major cause of sporadic cases of
autochthonous HEV in Europe [2,5–8]. Most of the infections with HEV
genotype 3 are asymptomatic. If symptoms occur, the clinical picture
can vary widely. HEV often presents as an acute viral hepatitis similar
to other viral hepatitides. However, some patients exhibit subacute or
fulminant acute liver failure [1–9]. HEV can also be complicated by
serious complications such as neurologic disorders or chronic hepatitis
[1–9]. In our study, two of the HEV IgM and RNA positive patients had
a clinical picture of an acute viral hepatitis, one was asymptomatic, and
the last suﬀered an acute hepatic failure which necessitated an urgent
liver transplantation. All four patients were male, aged 41–63 years.
According to the literature, HEV genotype 3 infections most frequently
aﬀect middle-aged or elderly persons. Men outnumber women [2–9].
However, these ﬁndings may reﬂect a predisposition of clinically ap-
parent disease rather than a diﬀerent infection rate depending on age or
gender [4,5,7].
HEV IgM was found positive in 6 patients (8,5%). Other studies in
Europe report similar numbers (5–15%) [6]. HEV RNA was ﬁnally de-
tected in 4 out of 6 HEV IgM positive samples. However the utility of
PCR is limited due to the short period of detectable HEV viremia. As has
been seen in patient 4, a negative PCR result on a sample positive for
HEV IgM cannot completely rule out an acute HEV infection which is
consistent with the published literature [2,5–9]. On the other hand,
commercial HEV ELISA assays also show a wide variety in sensitivity
and speciﬁcity [1–9]. Thus, a suboptimal speciﬁcity, for example due to
cross-reactivity, could also explain positive results for HEV IgM.
As expected, sequencing results of the HEV strains found in this
study revealed two strains belonged to genotype 3. One was subtyped as
genotype 3f, the other as genotype 3 h. Genotype 3 h consists of animal
and human strains and has been isolated in Italy, Uruguay and New
Zealand [6,8]. Genotype 3f comprises human, swine and sewage strains
isolated from Japan, Thailand, New Caledonia and most European
countries [6,8].
Several anti-HEV IgG seroprevalence studies on blood donors or
patient groups at risk for HEV infection have been carried out in
European countries. These studies show a signiﬁcant variability among
diﬀerent geographical areas [6]. Belgian data on patients at risk for
HEV were lacking. HEV IgG seroprevalence in this study was 18,3% and
slightly higher but not signiﬁcantly diﬀerent from the seroprevalence in
the general population in our region in Belgium reported to be 14% (p-
value 0.41) [10]. Diﬀerences in patient populations might explain these
ﬁndings. Van Hoecke et al. [10] used randomly selected, asymptomatic
patients presenting at the gynaecological or orthopaedic clinics of the
Ghent University Hospital. The average age of the individuals was 45
years (range 17–82 years). The male/female ratio was 1. The patients in
our study comprised a population at risk for HEV infection. Moreover,
the patients were slightly older (mean age 48 years, range 15–75 years)
and there was a small preponderance of male (58%), both risk factors
for (clinically apparent) HEV infection [4,5,7].
Our ﬁndings suggest that serology is useful as a screening tool for
HEV infection in a patients at risk for HEV. HEV RNA PCR can be used
in HEV IgM positive patients to conﬁrm the diagnosis of an acute HEV
infection, as a baseline for patients follow-up and for diagnosis of a
chronic HEV infection. We were unable to show an added value of
screening all patients with HEV RNA PCR, probably because of the
small sample size, heterogeneous composition of studied population
and a short period of HEV viremia. The results needs to be conﬁrmed in
other speciﬁc patient populations.
HEV should be considered as a cause of liver pathology especially in
middle-aged men with elevation of liver enzymes. The prevalence of
conﬁrmed acute HEV infection was 5,6% in the studied University
Hospital population in East and West Flanders. The seroprevalence of
HEV IgG was 18,3%. The fact that during>3 years period of the cur-
rent prospective study only 71 patients were included based on their
clinical presentation may reﬂect the rather low awareness among
medical professionals of the importance of HEV infection in liver pa-
thology. This accentuates the importance of future research in this
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Table 2
Lab results of the HEV IgM positive patients.
Patient Group Sample date HEV IgG HEV IgM HEV RNA HEV genotype Sample date ALT (U/L) AST (U/L) GGT (U/L) AP (U/L) BIL (mg/dL)
1 b 13/04/2011 pos pos pos 3f 13/04/2011 5045 2891 445 498 13
2 d 25/07/2013 pos pos pos 3h 23/03/2013 1166 2412 281 185 23,5
3 b 10/03/2011 pos pos pos /a 24/02/2011 1452 499 559 253 0,5
4 a 29/08/2013 pos pos posb /a 09/07/2013 250 215 215 225 0,6
Lab results of the HEV IgM positive patients. Alanine transaminase (ALT), reference range 7–40 U/L for males; Aspartate aminotransferase (AST), reference range
0–37 U/L for males; Gamma-glutamyl transpeptidase (GGT), reference range 0–37 U/L for males; Alkaline phosphatase (AP), reference range 30–120 U/L for males;
Total bilirubin (BIL), reference range 0,2–1,3 mg/dL.
a Technically failed.
b The original analysis on the study sample (29/08/2013) for HEV RNA was negative while HEV PCR in the NRC was positive on an earlier sample with elevated
liver enzymes (09/07/2013).
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